Adaptive Biotechnologies Corp Income Statement

Income Statement Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 38.45M55.66M85.07M98.38M154.34M185.31M170.28M178.96M
Cost of Revenue 16.77M24.49M38.45M61.36M95.47M95.60M88.58M84.76M
Gross Profit 21.68M31.18M46.62M37.02M58.88M89.70M81.70M94.20M
Operating items
Amortization - Intangibles 1.69M1.70M1.70M1.70M1.70M1.70M1.70M1.70M
Research & Development 32.00M39.16M70.70M116.07M142.34M141.76M122.12M102.95M
Selling, General & Administrative 15.95M20.41M30.33M49.54M74.50M88.53M83.93M72.81M
Restructuring Costs 0.84M
Other Operating Expenses 34.14M45.85M62.42M85.59M146.47M155.21M191.26M165.75M
Operating Expenses 82.92M105.42M163.46M251.20M363.31M385.49M397.31M341.51M
Operating Income -44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-227.03M-162.55M
EBIT -44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-227.03M-162.55M
Non-operating items
Interest & Investment Income 1.64M3.31M9.79M6.59M1.67M4.06M15.53M14.53M
Net income details
EBT -42.83M-46.45M-68.61M-146.23M-207.30M-200.37M-225.30M-159.59M
Profit After Tax -42.83M-46.45M-68.61M-146.23M-207.30M-200.37M-225.30M-159.59M
Income from Non-Controlling Interests -0.02M-0.18M-0.05M-0.10M
Income from Continuing Operations -42.83M-46.45M-68.61M-146.23M-207.30M-200.37M-225.30M-159.59M
Consolidated Net Income -42.83M-46.45M-68.61M-146.23M-207.30M-200.37M-225.30M-159.59M
Income towards Parent Company -42.83M-46.45M-68.61M-146.23M-207.30M-200.37M-225.30M-159.59M
Preferred Dividend Payments -0.14M-0.10M0.96M
Net Income towards Common Stockholders -42.70M-46.34M-69.57M-146.23M-207.28M-200.37M-225.30M-159.59M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 120.97M124.34M136.77M141.13M143.01M144.77M147.58M
Shares Outstanding (Diluted Average) 131.22M140.35M142.52M144.38M147.10M
EBITDA -44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-227.03M-162.55M